Open Actively Recruiting

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

About

Brief Summary

Duchenne muscular dystrophy (DMD) is a devastating X-linked disease which leads to loss of ambulation between ages 7 and 13, respiratory failure and cardiomyopathy (CM) at any age, and inevitably premature death of affected young men in their late twenties. DMD is the most common fatal genetic disorder diagnosed in childhood. It affects approximately 1 in every 3,500 live male births across all races and cultures, and results in 20,000 new cases each year worldwide.Significant advances in respiratory care have unmasked CM as the leading cause of death. As there are yet no specific cardiac treatments to extend life, the current study aims to address this unmet medical need using a new therapeutic strategy for patients with DMD.

Funding Source - FDA OOPD

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 2

Eligibility

Gender
Male
Healthy Volunteers
No
Minimum Age
7 Years
Maximum Age
N/A

Inclusion criteria:

Exclusion criteria:

Join this Trial

Share:
Study Stats
Protocol No.
19-001022
Category
Brain/Neurological Diseases
Contact
Selena Ridge
Location
  • UCLA Westwood
For Providers
NCT No.
NCT03340675
For detailed technical eligibility, visit ClinicalTrials.gov.